Join our Mailing list!
Get all latest news from Flavocure Biotech
Dr. Henry Lowe is the founder of Flavocure Biotech Inc and lead inventor of the company’s IP. He is also an Adjunct Professor at the University of Maryland School of Medicine. Dr. lowe is internationally recognized for his research in the field of drug discovery and development and has extensively studied the potential for plant-based compounds to treat a range of chronic diseases – including cancers, diabetes and viral diseases. His experience includes being the Chairman & CEO of Blue Cross Blueshield of Jamaica. Dr. Lowe hold a PhD in Medicinal Chemistry (Manchester University, UK) and is the co-author of several peer-reviewed articles and holder of 7 patents on his scientific inventions.
Dr. Ngeh Toyang is a co-founder of Flavocure Biotech and has over 20 years of research experience in the field of natural products and pharmacognosy at various research institutions including the National Center for Natural Products Research at the University of Mississippi School of Pharmacy; Natural Products Research Laboratory of the University of Leiden, The Netherlands, and the Institute of Human Virology of the University of Maryland School of Medicine. Dr. Toyang holds a PhD degree specializing in Pharmacognosy from Leiden University, The Netherlands. He is the co-author of over 30 peer-reviewed scientific articles and holds 9 patents on his scientific inventions including the IP protection for Caflanone. Under his leadership, Flavocure Biotech has applied and received two FDA Orphan Drug Designations.
Dr. David Brooks has over 15 years of experience in drug development leading clinical and translational research. Dr. Brooks has overseen and/or led the 2 drugs that have been approved by the US FDA. He has extensive experience preparing all the clinical and biomarker sections for 9 IND applications over the last 16 years. All of these clinical research projects have involved extremely close communication, coordination and collaboration with leading academic institutions throughout the USA and the biotechnology companies. He has specific experience planning and overseeing pancreatic adenocarcinoma clinical trials which led to the (very rare) successful approval of Abraxane for this tumor type. Dr. Brooks holds MD and PhD degrees from Cornell University.
Thomas Lang is an experienced pharmaceutical and biotech industry veteran, graduating with degrees in Chemistry and Pharmacy. Dr. Lang previously served as the President and Vice Chairman of Serono, Inc., a biopharmaceutical business headquartered in Geneva, Switzerland. He has participated in the successful development and commercialization of 12 products in the areas of HIV/AIDS, Infertility and Reproductive Health, Growth, Metabolism and Endocrinology, CNS, Surgical Muscle Relaxants, Allergy Immunotherapy, and Multiple Sclerosis. At Flavocure he oversees the implementation of all IND-enabling studies and preparation of the IND filing package with the FDA.
Douglas graduated magna cum laude from The Ohio State University with a bachelor’ s degree in Finance and International Business. He has served in various corporate finance/accounting capacities in several publicly-traded biotech companies for over 20 years and was instrumental in SEC reporting and multiple rounds of public and private financing in those companies.
Dr. Henry Lowe is the founder of Flavocure Biotech Inc and lead inventor of the company’s IP. He is also an Adjunct Professor at the University of Maryland School of Medicine. Dr. lowe is internationally recognized for his research in the field of drug discovery and development and has extensively studied the potential for plant-based compounds to treat a range of chronic diseases – including cancers, diabetes and viral diseases. His experience includes being the Chairman & CEO of Blue Cross Blueshield of Jamaica. Dr. Lowe hold a PhD in Medicinal Chemistry (Manchester University, UK) and is the co-author of several peer-reviewed articles and holder of 7 patents on his scientific inventions.
Dr. Ngeh Toyang has over 15 years of research experience in the field of natural products and pharmacognosy at various research institutions including the National Center for Natural Products Research at the University of Mississippi School of Pharmacy; Natural Products Research Laboratory of the University of Leiden, The Netherlands and the Institute of Human Virology of the University of Maryland School of Medicine. Dr. Toyang holds a PhD in Pharmacognosy from Leiden University, The Netherlands. He is the co-author of several peer-reviewed journal articles including 7 patents on his scientific inventions including the IP protection for Caflanone. His leadership resulted in Flavocure obtaining two FDA Orphan Drug Designations.
David Afzali is the Founder and Chief Executive Officer of Innocatalyze Life Sciences, where he works directly with senior biopharmaceutical leadership to identify and introduce strategically relevant innovation platforms supporting enterprise priorities across commercialization, patient access, and digital enablement. Over a career spanning more than three decades in the global life sciences sector, he has held senior leadership roles across both pharmaceutical companies and leading global consulting organizations. Earlier in his career, David worked within the pharmaceutical industry at organizations including E. Merck (Germany), Sartorius Biotech, Cal Biotech, Endogen, and Oncogene Sciences. He later held senior leadership positions at EY, Capgemini, PA Consulting, IBM Global Business Services, advising many of the world’s leading pharmaceutical companies on growth strategy, commercialization infrastructure, and digital transformation. Throughout his career, he has worked extensively with senior leadership across major biopharma organizations including Johnson & Johnson, Pfizer, Eli Lilly, Regeneron, Merck, AbbVie, and others. He is widely recognized for his deep industry relationships and his ability to bridge emerging innovation with the strategic priorities of large pharmaceutical enterprises.
Medicinal chemist with expertise in phytomedicine, natural product chemistry, the design and synthesis of complex organic molecules, small molecule–protein–enzyme interactions, and nanomedicine/targeted drug delivery systems. Dr. Tanifum is an Associate Professor, Baylor College of Medicine
Anthony Deasey is a Chartered Accountant with over 35 years of experience as Chief Financial Officer in both public and private companies. For the last 16 years he has served as CEO, COO and CFO in privately and publicly held medical and biotech companies where he has led financing and raised an excess of $100M with 2 successful exits.
Sewaa Strategies, a strategic advisor to Flavocure, is an innovative biopharma advisory firm. We specialize in creating exponential patient and shareholder value via bridging capital efficient clinical development and complementary business alliances. Sewaa Strategies has successfully developed product portfolios in oncology, autoimmune inflammatory diseases, neurosciences and rare diseases. We offer end to end expertise in business development, business strategy and operational scale up for pre series A to publicly traded biotech companies. Saurabh Sewak, CEO of Sewaa Strategies is a biotech veteran, and has held senior positions at Biogen, TESARO (now GSK), Ispen and currently Foghorn Therapeutics. At Biogen he was the global head of Commercial Assessment and Disease Strategy and built the Commercial Operations capability. At TESARO he led the development of PARPi and PD-1 inhibitors in multiple oncology indications. At Ipsen Saurabh was the Head of the Medical Science Liaison organization for neuroscience and rare diseases. He currently serves as the VP of corporate development at Foghorn Therapeutics. Saurabh is also a Board Vice Chair for the Leukemia and Lymphoma Society New England Region. He is a pharmacist by primary training and received his MS and PhD degrees in Health Care Administration from the University of Mississippi.
Dr. Woolf graduated from the University of Washington (Seattle, Washington) with a BS in Pharmacy; University of California (San Francisco) Ph.D. Pharmaceutical Chemistry and was a Postdoctoral Fellow in Organic Chemistry at John’s Hopkins University School of Medicine. For several years Dr. Woolf has served as a Pharmacokinetics and Drug discovery specialist/consultant for some of the leading pharmaceutical companies such as Pfizer, Inc. Park- Davis/Warner Lambert Co, and Elan Pharmaceuticals. Dr. Woolf is credited for playing a role in the discovery and development Lipitor®. Dr. Woolf has also served for many years as a consultant on drug regulatory affairs, pharmaceutical investment due diligence, and patent issues. Dr. Woolf is also a registered Patent Agent with the USPTO. He is the Author / Co-author of 45, peer-reviewed articles and contributed to the “Handbook of Drug Metabolism”. He was also Associate Editor for the “Journal of Pharmacology and Experimental Therapeutics”. Dr. Woolf is the holder of several honors and awards in his professional field.
Subscribe to Receive News from Flavocure Biotech
Get all latest news from Flavocure Biotech